To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol 2018; 24(27): 2949-2973 [PMID: 30038463 DOI: 10.3748/wjg.v24.i27.2949]
Corresponding Author of This Article
Kenneth KW To, PhD, Associate Professor, School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Room 801N, Lo Kwee Seong Integrated Biomedical Sciences Building, Area 39, Shatin, New Territories, Hong Kong, China. kennethto@cuhk.edu.hk
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 21, 2018; 24(27): 2949-2973 Published online Jul 21, 2018. doi: 10.3748/wjg.v24.i27.2949
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside
Kenneth KW To, Christy WS Tong, Mingxia Wu, William CS Cho
Kenneth KW To, Christy WS Tong, Mingxia Wu, School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, China
William CS Cho, Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China
Author contributions: All authors contributed equally to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the submitted version.
Supported bythe Direct Grant for Research, Faculty of Medicine, the Chinese University of Hong Kong, No. 4054371.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kenneth KW To, PhD, Associate Professor, School of Pharmacy, Faculty of Medicine, the Chinese University of Hong Kong, Room 801N, Lo Kwee Seong Integrated Biomedical Sciences Building, Area 39, Shatin, New Territories, Hong Kong, China. kennethto@cuhk.edu.hk
Telephone: +852-39438017 Fax: +852-26035295
Received: May 2, 2018 Peer-review started: May 4, 2018 First decision: June 6, 2018 Revised: June 28, 2018 Accepted: June 30, 2018 Article in press: June 30, 2018 Published online: July 21, 2018 Processing time: 79 Days and 13 Hours
Core Tip
Core tip: MicroRNAs (miRNAs) are important mediators regulating the initiation, progression, metastasis and recurrence of colorectal cancer (CRC). Numerous studies have reported dysregulation of miRNAs in tumor specimens and body fluids, including serum, plasma and feces. Furthermore, the miRNAs were more recently found in circulating exosomes from CRC patients. Fortunately, this finding suggests potential diagnostic, prognostic and therapeutic applications of miRNAs at different stages of CRC. In this review, we aim to outline the current body of knowledge pertaining to the critical roles played by miRNAs in the molecular pathogenesis of CRC. Our focus is to delineate practical applications of miRNAs as prognostic biomarkers and therapeutic targets in the treatment of CRC.
